No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
骨粗鬆症患者におけるイバンドロネート経口製剤とエルデカルシトールの併用療法の検討
Rent:
Rent this article for
JPY
Abstract
The efficacy of the combination therapy of monthly oral ibandronate and eldecalcitol in 57 osteoporosis patients was compared by using tartrate‒resistant acid phosphatase‒5b(TRACP‒5b)levels, and the safety was also determined. When determined in 2 groups of those whom the osteoporosis therapy was newly introduced and those whom the osteoporosis therapy was switched from risedronate, the TRACP5‒b level significantly decreased in both groups, which showed a significant difference especially in female patients(p<0.001). Secondly, while fasting duration after dosing is 60 minutes for the monthly product of monthly oral ibandronate, which is longer than that of existing bisphosphonate products, the survey with patient questionnaire showed that 81% of patients did not have any changes in their daily morning life. It is considered that their life style did not suffer any changes.
Full text loading...
/content/article/0289-8020/38050/527